MET and glioblastoma: Velpula et al. (2012) demonstrated that GBM cell lines (U251 and 5,310) cultured with or without human umbilical cord blood stem cells (hUCBSCs) exhibited differential response to treatment with EGFR inhibitors, erlotinib, and gefitinib, used in combination with the c-Met inhibitor PHA-665752.